TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) EPS (Basic) : $-1.65 (TTM As of Sep. 2016)

View and export this data going back to 2013. Start your Free Trial

What is TetraLogic Pharmaceuticals EPS (Basic)?

TetraLogic Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2016 was $-0.35. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.65.

TetraLogic Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2016 was $-0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.65.

TetraLogic Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2016 was $-0.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2016 was -1.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

TetraLogic Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for TetraLogic Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TetraLogic Pharmaceuticals EPS (Basic) Chart

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

EPS (Basic)

-17.36

-20.26

-10.11

-1.61

-2.10

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
EPS (Basic)	Get a 7-Day Free Trial														-0.46	-0.58	-0.45	-0.27	-0.35

TetraLogic Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

TetraLogic Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2015 is calculated as

Basic EPS (A: Dec. 2015 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-49.724	-	0)	/	23.692
	=	-2.10

TetraLogic Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2016 is calculated as

Basic EPS (Q: Sep. 2016 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.635	-	0)	/	24.769
	=	-0.35

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.65

TetraLogic Pharmaceuticals (OTCPK:TLOG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

TetraLogic Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TetraLogic Pharmaceuticals Corp (OTCPK:TLOG) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Phoenixville Pike, Malvern, PA, USA, 19355

Website

http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.

Executives

Hudson Bay Capital Management Lp	other: See Remarks	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Lazard Asset Management Llc	other: See Remarks	30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112
Nomura Holdings Inc	other: See Remarks	1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645
Whitebox Multi-strategy Partners Lp	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Pandora Select Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox General Partner Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416
Highbridge Capital Management Llc	other: See Remarks	277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Sander Gerber	other: See Remarks	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Whitebox Concentrated Convertible Arbitrage Partners, L.p.	other: See Remarks	3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416
Whitebox Advisors Llc	other: See Remarks	3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416
Patrick Hutchison	officer: CFO & Treasurer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
Clarus Ventures Ii, Llc	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Ii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Ventures Ii Gp, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Nicholas Simon	10 percent owner	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

TetraLogic Pharmaceuticals (TetraLogic Pharmaceuticals) Headlines

No Headlines